{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-022597","form_type":"8-K","ticker":"IRWD","cik":"0001446847","company_name":"IRONWOOD PHARMACEUTICALS INC","filed_at":"2023-02-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.039614+00:00","generated_at":"2026-06-19T09:10:10.689827+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ironwood reports FY 2022 GAAP net income $175M; FDA grants priority review for LINZESS pediatric sNDA","bullets":["FY 2022 total revenues $410.6M (down ~1% YoY); GAAP net income $175.1M vs $528.4M in FY 2021.","Q4 2022 total revenues $107.2M; GAAP net income $48.9M ($0.27 diluted EPS).","Adjusted EBITDA for FY 2022 was $252M, up from $234M in FY 2021; cash and equivalents $656M.","FDA granted priority review for LINZESS sNDA for pediatric functional constipation (ages 6-17); PDUFA date Q2 2023.","CEO cited robust prescription demand but lower LINZESS sales growth due to retail channel inventory fluctuations."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-022597","json":"https://secwatch.observer/filing/0001104659-23-022597.json","markdown":"https://secwatch.observer/filing/0001104659-23-022597.md","text":"https://secwatch.observer/filing/0001104659-23-022597.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446847/000110465923022597/0001104659-23-022597-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446847/000110465923022597/tm236845d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T09:10:10.689827+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"90c5ffd26523608e90a1f7839c50eb1d29b61c4f","claim":"IRONWOOD PHARMACEUTICALS INC reported financial results for quarter and year ended December 31, 2022.","evidence_excerpt":"On February 16, 2023, Ironwood Pharmaceuticals, Inc. issued a press release containing an update on its recent business activities as well as those for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1446847/000110465923022597/0001104659-23-022597-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}